A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1.0% and 2.5% Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Trial Profile

A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1.0% and 2.5% Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2016

At a glance

  • Drugs Urocanic acid (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Sponsors Herantis Pharma
  • Most Recent Events

    • 04 Jan 2016 Primary endpoint has not been met. (Symptom Score), as reported by Herantis media release.
    • 04 Jan 2016 Primary endpoint has not been met. (Corneal Fluorescein Staining), as reported by Herantis media release.
    • 08 Sep 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top